<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358432</url>
  </required_header>
  <id_info>
    <org_study_id>AK102-203</org_study_id>
    <nct_id>NCT04358432</nct_id>
  </id_info>
  <brief_title>A Phase II Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study of AK102 in the Treatment of Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AD Pharmaceuticals Co., Ltd. (Guangzhou)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the
      safety and efficacy of AK102 in patients with Hypercholesterolemia Patients at Very High or
      High Risk of Cardiovascular Disease .

      The primary objective of this study is to evaluate the efficacy of AK102 in patients with
      Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease .
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 12</measure>
    <time_frame>At baseline and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in high-density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non High-density lipoprotein (non-HDL) cholesterol</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in serum Triglyceride (TG) cholesterol</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Apolipoprotein A-I (ApoA-I)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Lipoprotein(a) [Lp-(a)]</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in Total Cholesterol(TC)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of AK102</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
    <description>The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proprotein convertase subtilisin/kexin type 9 (PCSK9)</measure>
    <time_frame>From baseline through 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>AK102 450 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AK102 450 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK102 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AK102 300 mg subcutaneous injection once every 4 weeks (Q4W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK102 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AK102 150 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK102 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AK102 75 mg subcutaneous injection once every 2 weeks (Q2W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK102</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>AK102 150 mg</arm_group_label>
    <arm_group_label>AK102 300 mg</arm_group_label>
    <arm_group_label>AK102 450 mg</arm_group_label>
    <arm_group_label>AK102 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Administered by subcutaneous injection</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statins and/or Ezetimibe</intervention_name>
    <description>Lipid-lowering therapies</description>
    <arm_group_label>AK102 150 mg</arm_group_label>
    <arm_group_label>AK102 300 mg</arm_group_label>
    <arm_group_label>AK102 450 mg</arm_group_label>
    <arm_group_label>AK102 75 mg</arm_group_label>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily sign the informed consent form (ICF), and be able to comply with the
             treatment plan, visit, laboratory examination and other requirements specified in the
             study;

          2. Age ≥ 18, male or female;

          3. According to the guidelines for the prevention and treatment of dyslipidemia in
             Chinese adults (revised in 2016), subjects assessed as very high risk or high risk of
             cardiovascular disease;

          4. Subjects received stable and optimal dose of statins for at least 4 weeks before
             randomization, either in combination with or without ezetimibe;

          5. The blood lipid level of the patients with stable 4-week basic lipid-lowering drug
             treatment met one of the following conditions by the central laboratory test: LDL-C
             level in very high risk subjects &gt; 1.8 mmol / L (70 mg / dl) or LDL-C level of
             high-risk subjects &gt; 2.6 mmol / L (100 mg / dl)

          6. TG ≤ 4.5 mmol / L (400 mg / dl) measured by central laboratory at screening；

        Exclusion Criteria:

          1. Has received cholesterol ester transfer protein (CETP) inhibitor within12 months prior
             to randomization;

          2. Has received PCSK9 inhibitors or are known to be allergic to PCSK9 inhibitors or their
             components;

          3. Has received other investigational drugs within 4 weeks or within 5 half lives
             (whichever was longer) prior to screening.

          4. Has previously received biological agent treatment, organ transplantation or gene
             therapy;

          5. Abnormal laboratories prior to the first study drug administration: ALT or AST＞ 3 ×
             ULN; Creatine kinase &gt; 5 × ULN; eGFR &lt;= 30 ml/min/1.73m2 by Cockcroft Gault method;

          6. Uncontrolled hypothyroidism or hyperthyroidism defined as TSH &lt; 1.0 ×LLN or &gt; 1.5 ×
             ULN, respectively;

          7. Myocardial infarction, unstable angina pectoris, percutaneous coronary intervention
             (PCI), coronary bypass grafting (CABG), stroke, severe deep vein thrombosis or
             pulmonary embolism, or severe arrhythmia occurred within three months prior to
             randomization ;

          8. Grade III or IV according to NYHA assessment;

          9. Planned to have heart-related surgery within 3 months after randomization;

         10. Type 1 diabetes or poorly controlled type 2 diabetes [HbA1c &gt; 8.5% within 1 month];

         11. Subjects with hypertension that could not be controlled by drugs;

         12. Known concomitant diseases that may lead to secondary hyperlipidemia, including
             nephrotic syndrome, cholestatic liver failure, etc;

         13. Positive HBsAg or HCV antibody;

         14. Known history of primary immunodeficiency virus infection or positive human
             immunodeficiency virus (HIV) test;

         15. History of drug or alcohol abuse prior to screening;

         16. Has taken the following drugs within 6 weeks prior to screening: red koji rice &gt; 200
             mg/day; niacin &gt; 1000 mg/day; omega-3 fatty acids; steroids or prescription lipid
             regulating drugs ; cholesterol lowering drugs, health care products, Chinese patent
             medicines or other food additives other than statins and ezetimibe;

         17. Has taken the following drugs within 3 months prior to screening: systemic
             cyclosporine, systemic steroids, vitamin A derivatives and retinol derivatives for the
             treatment of skin diseases (such as retinoic acid).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhong Shan Hospital Fu Dan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Liu</last_name>
    <phone>86 (0760) 8987 3999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhong Shan Hosipital Fu Dan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>zhen wang</last_name>
    </contact>
    <investigator>
      <last_name>Junbo Ge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

